Nicolas Schleinitz

Nicolas Schleinitz

Auto-generated profile, based on publicly available information

Nicolas Schleinitz

Département de Médecine Interne, Timone Hospital, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille Université, Marseille, France

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2015 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
AKA. Khosroshahi
A. Khosroshahi
ZWZ. S. Wallace
Z. S. Wallace
JCJ. L. Crowe
J. L. Crowe
TAT. Akamizu
T. Akamizu
AAA. Azumi
A. Azumi
JSJ. H. Stone
J. H. Stone

2 December 2019 in Arthritis & Rheumatology
Verified
Journal Article
Closed access
PDF file
ZWZachary S. Wallace
Zachary S. Wallace
RNRay P. Naden
Ray P. Naden
SCSuresh Chari
Suresh Chari
HCHyon Choi
Hyon Choi
EDEmanuel Della-Torre
Emanuel Della-Torre
GWGeorge Webster
George Webster

11 December 2012 in Gut
Verified
Journal Article
Open access
PDF file
PHPhil A Hart
Phil A Hart
TKTerumi Kamisawa
Terumi Kamisawa
WBWilliam R Brugge
William R Brugge
JCJae Bock Chung
Jae Bock Chung
ECEmma L Culver
Emma L Culver
SCSuresh T Chari
Suresh T Chari
Objective Autoimmune pancreatitis (AIP) is a treatable form of chronic pancreatitis that has been increasingly recognised over the last decade. We set out to better understand the current burden of AIP at several academic institutions diagnosed using the International Consensus Diagnostic Criteria, and to describe long-term outcomes, including organs involved, treatments, relapse frequency and long-term sequelae. Design 23 institutions from 10 different countries participated in this multinational analysis. A total of 1064 patients meeting the International Consensus Diagnostic Criteria for type 1 (n=978) or type 2 (n=86) AIP were included. Data regarding treatments, relapses and sequelae were obtained. Results The majority of patients with type 1 (99%) and type 2 (92%) AIP who were treated with steroids went into clinical remission. Most patients with jaundice required biliary stent placement (71% of type 1 and 77% of type 2 AIP). Relapses were more common in patients with type 1 (31%) versus type 2 AIP (9%, p<0.001), especially those with IgG4-related sclerosing cholangitis (56% vs 26%, p<0.001). Relapses typically occurred in the pancreas or biliary tree. Retreatment with steroids remained effective at inducing remission with or without alternative treatment, such as azathioprine. Pancreatic duct stones and cancer were uncommon sequelae in type 1 AIP and did not occur in type 2 AIP during the study period. Conclusions AIP is a global disease which uniformly displays a high response to steroid treatment and tendency to relapse in the pancreas and biliary tree. Potential long-term sequelae include pancreatic duct stones and malignancy, however they were uncommon during the study period and require additional follow-up. Additional studies investigating prevention and treatment of disease relapses are needed.

15 May 2008 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
EOEric Oksenhendler
Eric Oksenhendler
LGLaurence Gérard
Laurence Gérard
CFClaire Fieschi
Claire Fieschi
MMMarion Malphettes
Marion Malphettes
GMGael Mouillot
Gael Mouillot
DGDEFI Study Group
DEFI Study Group
Background. Common variable immunodeficiency is characterized by recurrent infections and defective immunoglobulin production.

1 November 2017 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
AFAlain Fischer
Alain Fischer
JPJohan Provot
Johan Provot
JJJean-Philippe Jais
Jean-Philippe Jais
AAAlexandre Alcais
Alexandre Alcais
NMNizar Mahlaoui
Nizar Mahlaoui
JVJean-François Viallard
Jean-François Viallard

15 November 2005 in Blood
Verified
Journal Article
Closed access
PDF file
KMKarin Mazodier
Karin Mazodier
VMValérie Marin
Valérie Marin
DNDaniela Novick
Daniela Novick
CFCatherine Farnarier
Catherine Farnarier
SRStéphane Robitail
Stéphane Robitail
GKGilles Kaplanski
Gilles Kaplanski
Hemophagocytic syndrome (HPS) is characterized by an uncontrolled and poorly understood activation of T-helper 1 (Th-1) lymphocytes and macrophages. We studied 20 patients with HPS secondary to infections, autoimmune disease, lymphoma, or cancer and observed that the concentrations of serum interleukin 18 (IL-18), a strong inducer of Th-1 responses, interferon γ (IFN-γ) production, and stimulation of macrophages and natural killer (NK) cells were highly increased in HPS but not in control patients. In contrast, concentrations of its natural inhibitor, the IL-18 binding protein (IL-18BP), were only moderately elevated, resulting in a high level of biologically active free IL-18 in HPS (4.6-fold increase compared with controls; P < .001). Free IL-18 but not IL-12 concentrations significantly correlated with clinical status and the biologic markers of HPS such as anemia (P < .001), hypertriglyceridemia, and hyperferritinemia (P < .01) and also with markers of Th-1 lymphocyte or macrophage activation, such as elevated concentrations of IFN-γ and soluble IL-2 and tumor necrosis factor α (TNF-α) receptor concentrations. Despite high IL-18 elevation, in vitro NK-cell cytotoxicity was severely impaired in HPS patients, in part due to NK-cell lymphopenia that was observed in a majority of patients but also secondary to an intrinsic NK-cell functional deficiency. We concluded that a severe IL-18/IL-18BP imbalance results in Th-1 lymphocyte and macrophage activation, which escapes control by NK-cell cytotoxicity and may allow for secondary HPS in patients with underlying diseases.